Table 2.
Tumour characteristics and trans-arterial chemoembolization (TACE) treatment among the cohort
| TACE cohort (n= 78) | No BR (n= 54) | BR (n= 24) | P-value | |
|---|---|---|---|---|
| Pre-procedure AFP level [median, (range)] | 47.0 (1.3–524 000) | 47.0 (1.3–524 000) | 44.5 (2.0–4787) | 0.830 |
| Post-procedure AFP level [median, (range)] | 24.6 (1.4–58 623) | 37.6 (1.8–58 623) | 23.1 (1.4–2668) | 0.922 |
| Diameter of largest tumour (cm) [median (range)] | 4.4 (0.7–12.1) | 4.2 (0.7–12.1) | 4.8 (2.1–12.1) | 0.700 |
| More than one tumour [n (%)] | 48 (61.5) | 34 | 14 | 0.802 |
| Location of tumour (s) | ||||
| Right lobe [n (%)] | 36 (46.2) | 22 | 14 | 0.219 |
| Left lobe [n (%)] | 7 (9.0) | 4 | 3 | 0.670 |
| Bilobar [n (%)] | 35 (44.8) | 28 | 7 | 0.085 |
| TACE procedure details | ||||
| Selective TACE (smaller than hepatic arteries) [n (%)] | 9 (11.5) | 6 | 3 | 1.000 |
| Chemotherapy TACE [n (%)] | 37 (47.5) | 23 | 14 | 0.227 |
| TACE with chemo-coated beads [n (%)] | 24 (30.7) | 17 | 7 | 1.000 |
| Bland TACE (embolization) [n (%)] | 17 (21.8) | 14 | 3 | 0.242 |
AFP, Alpha-feto protein.